Acropolis Investment Management LLC raised its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 326.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,735 shares of the biopharmaceutical company’s stock after buying an additional 6,688 shares during the quarter. Acropolis Investment Management LLC’s holdings in Bristol-Myers Squibb were worth $535,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Bristol-Myers Squibb by 0.3% in the second quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after purchasing an additional 333,685 shares in the last quarter. BlackRock Inc. raised its stake in shares of Bristol-Myers Squibb by 2.4% in the second quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after purchasing an additional 2,367,864 shares in the last quarter. Dodge & Cox raised its stake in shares of Bristol-Myers Squibb by 1.6% in the second quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after purchasing an additional 459,271 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Bristol-Myers Squibb by 16.2% in the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after purchasing an additional 3,735,453 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Bristol-Myers Squibb by 3.9% in the second quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after purchasing an additional 910,496 shares in the last quarter. Institutional investors own 69.56% of the company’s stock.

Bristol-Myers Squibb Co (NYSE BMY) opened at $63.16 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Co has a 12 month low of $51.56 and a 12 month high of $66.10. The stock has a market capitalization of $103,370.00, a price-to-earnings ratio of 107.05, a price-to-earnings-growth ratio of 1.94 and a beta of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 33.68% and a net margin of 4.85%. The firm had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the company posted $0.63 earnings per share. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. equities analysts anticipate that Bristol-Myers Squibb Co will post 3.22 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were paid a dividend of $0.40 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.53%. The ex-dividend date of this dividend was Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 271.19%.

BMY has been the subject of a number of recent research reports. Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Citigroup upped their target price on Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research note on Wednesday, October 18th. Vetr lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 target price for the company. in a research note on Tuesday, January 16th. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Monday, December 11th. Finally, Credit Suisse Group set a $62.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, January 22nd. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $65.58.

In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the sale, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Co (BMY) Shares Bought by Acropolis Investment Management LLC” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/bristol-myers-squibb-co-bmy-shares-bought-by-acropolis-investment-management-llc/1862471.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.